



Johnson & Johnson Vision Announces Health Canada has issued a Medical Device License for First-of-its-Kind Contact Lens ACUVUE OASYS with Transitions Light Intelligent Technology

Developed in strategic partnership with Transitions Optical, this first-of-its-kind¹ contact lens seamlessly adapts to changing light conditions while providing all-day soothing vision^{2,3}

MARKHAM, Ontario (November 6, 2018) – Johnson & Johnson Vision today announced ACUVUE OASYS with Transitions was issued a medical device license by Health Canada. ACUVUE OASYS with Transitions Light Intelligent Technology is a first-of-its-kind contact lens in Canada that offers benefits beyond vision correction by reducing exposure to bright light both indoors and outdoors.^{1,4} These lenses are indicated for the attenuation of bright light.

These contact lenses function by quickly and seamlessly adjusting from clear to dark in response to changing light conditions, balancing the amount of light entering the eye including filtering blue light, and blocking harmful UV rays.^{†4,5,6} ACUVUE OASYS with Transitions has created and defined an entirely new category of contact lenses that will help address unmet needs for patients.

“ACUVUE OASYS with Transitions is the result of more than a decade of product development and numerous clinical trials involving more than 1,000 patients,” said Ted Lachmansingh, Canada Business Director, Johnson & Johnson Vision. “This first-of-its-kind contact lens was born out of deep research into consumer lifestyle needs and provides wearers with a solution to help manage light in their modern, active lives.”

A range of everyday lighting situations, from artificial light to UV rays, can impact eye comfort and vision.^{7,8,9} ACUVUE OASYS with Transitions actively adapts to light conditions encountered throughout the day to balance the amount of light hitting the eye, and helps eyes adjust to changing light better than they would on their own.^{3,4}

This strategic partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical combines the respective strengths of each company. While ACUVUE is the world leader in contact lenses, Transitions Optical is the leading provider of photochromic (smart adaptive) lenses worldwide. Both companies are working to research and deliver best-in-class vision care innovations.

This regulatory milestone is an important step toward achieving Johnson & Johnson’s vision of helping people see better, connect better, and live better. The two-week reusable contact lens will be commercially available in the first half of 2019.

About Johnson & Johnson Vision

At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better and live better. Visit us at www.jjvision.com. Follow [@JNJVision](https://twitter.com/JNJVision) on Twitter and Johnson & Johnson Vision on [LinkedIn](https://www.linkedin.com/company/johnson-johnson-vision).

###

For further information, contact:

Kara Peterson
904.443.3480 (o)
817.374.3960 (m)
kpeter9@its.jnj.com



ACUVUE® Brand Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care division of Johnson & Johnson Inc., by calling 1-800-267-5098 or by visiting jnvisionpro.ca.

†Helps protect against transmission of harmful UV radiation to the cornea and into the eye.

‡WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care professional for more information.

The third-party trademarks used herein are trademarks of their respective owners.

ACUVUE OASYS is a trademark of Johnson & Johnson Inc.

© Johnson & Johnson Vision Care division of Johnson & Johnson Inc. 2018 CC18676

1 FDA Press Release: FDA clears first contact lens with light-adaptive technology <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604263.htm> April 10, 2018.

2 Defined as comfortable vision under bright light conditions.

3 JJV Data on File 2018: ACUVUE® OASYS with Transitions™ Objective Clinical

4 JJV Data on File 2018: Definition of ACUVUE® OASYS with Transitions™ Light Intelligent Technology™

5 Calculated per ISO-8980-3 for 380-460nm (Blue Light Hazard Function, B(A))

6 JJV Data on File 2018: Material Properties ACUVUE OASYS® Brand Contact Lenses with HYDRACLEAR® Plus and other reusable contact lenses

7 American Academy of Ophthalmology. What is Photokeratitis. Available at: <https://www.aao.org/eye-health/diseases/photokeratitis-snow-blindness>. Accessed 22 Jan 2018.

8 American Optometric Association. UV Protection. Available at: <https://www.aoa.org/patients-and-public/caring-for-your-vision/uv-protection>. Accessed 22 Jan 2018.

9 Walls HL, Walls KL, Benke G. Eye Disease Resulting From Increased Use of Fluorescent Lighting as a Climate Change Mitigation Strategy. American Journal of Public Health. 2011;101(12):2222-2225.